CA2638866C - Peptide based inhibition of capcna protein-protein interactions in cancer - Google Patents
Peptide based inhibition of capcna protein-protein interactions in cancer Download PDFInfo
- Publication number
- CA2638866C CA2638866C CA2638866A CA2638866A CA2638866C CA 2638866 C CA2638866 C CA 2638866C CA 2638866 A CA2638866 A CA 2638866A CA 2638866 A CA2638866 A CA 2638866A CA 2638866 C CA2638866 C CA 2638866C
- Authority
- CA
- Canada
- Prior art keywords
- capcna
- peptide
- protein
- pcna
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74331306P | 2006-02-17 | 2006-02-17 | |
| US60/743,313 | 2006-02-17 | ||
| PCT/US2007/062335 WO2007098415A2 (en) | 2006-02-17 | 2007-02-16 | Peptide based inhibition of capcna protein-protein interactions in cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2638866A1 CA2638866A1 (en) | 2007-08-30 |
| CA2638866C true CA2638866C (en) | 2015-11-10 |
Family
ID=38235155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2638866A Active CA2638866C (en) | 2006-02-17 | 2007-02-16 | Peptide based inhibition of capcna protein-protein interactions in cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8653039B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1989225A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009527498A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101384618A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007217037A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0707948A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2638866C (cg-RX-API-DMAC7.html) |
| EA (1) | EA200801847A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007098415A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200801847A1 (ru) * | 2006-02-17 | 2009-02-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | ПЕПТИДНОЕ ИНГИБИРОВАНИЕ ВЗАИМОДЕЙСТВИЯ caPCNA ПРИ РАКЕ |
| WO2008036929A2 (en) * | 2006-09-21 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | Complex for transferring an anionic substance into a cell |
| GB0803352D0 (en) | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| CA2732737C (en) * | 2008-07-24 | 2019-03-05 | Indiana University Research And Technology Corporation | Cancer peptide therapeutics |
| FR2942798B1 (fr) * | 2009-03-05 | 2011-04-08 | Centre Nat Rech Scient | Peptides utilisables pour le traitement de la leucemie lymphoide chronique |
| WO2011044374A1 (en) * | 2009-10-07 | 2011-04-14 | Indiana University Research And Technology Corporation | Capcna peptide therapeutics for cancer |
| EP2538959A1 (en) * | 2010-02-24 | 2013-01-02 | Institut National de la Santé et de la Recherche Médicale | Compounds for the treatment of inflammation and neutropenia |
| JP2013522613A (ja) * | 2010-03-18 | 2013-06-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 化学療法に対する応答性を予測するための方法 |
| US9475840B2 (en) | 2012-02-27 | 2016-10-25 | Universitat De Barcelona | Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs |
| GB201214007D0 (en) * | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
| US10420840B2 (en) * | 2015-04-10 | 2019-09-24 | Rll, Llc | Anticancer therapeutic agents |
| JP2020514256A (ja) * | 2016-12-15 | 2020-05-21 | ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ,リミテッド | 抗pcnaモノクローナル抗体及びその使用 |
| GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5935797A (en) | 1994-06-16 | 1999-08-10 | Stanford University | Interaction of MHC Class II proteins with members of the PCNA family of proteins |
| GB9509557D0 (en) * | 1995-05-11 | 1995-07-05 | Univ Dundee | PCNA binding substance |
| JP2002518341A (ja) * | 1998-06-15 | 2002-06-25 | アーチ・デヴェロップメント・コーポレイション | 放射線療法と抗血管形成因子の組み合わせ |
| US7294471B2 (en) | 2002-02-27 | 2007-11-13 | Cskeys, Llc | Method for purifying cancer-specific proliferating cell nuclear antigen |
| MX2007013584A (es) | 2005-04-27 | 2008-04-22 | Univ Indiana Res & Tech Corp | Anticuerpos de isoforma de cspcna y sus usos. |
| DE602006021178D1 (de) | 2005-06-27 | 2011-05-19 | Univ Indiana Res & Tech Corp | Cspcna-isoform-modifikationen und anwendungen davon |
| EA200801847A1 (ru) * | 2006-02-17 | 2009-02-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | ПЕПТИДНОЕ ИНГИБИРОВАНИЕ ВЗАИМОДЕЙСТВИЯ caPCNA ПРИ РАКЕ |
-
2007
- 2007-02-16 EA EA200801847A patent/EA200801847A1/ru unknown
- 2007-02-16 CA CA2638866A patent/CA2638866C/en active Active
- 2007-02-16 AU AU2007217037A patent/AU2007217037A1/en not_active Abandoned
- 2007-02-16 CN CNA2007800052894A patent/CN101384618A/zh active Pending
- 2007-02-16 JP JP2008555524A patent/JP2009527498A/ja active Pending
- 2007-02-16 BR BRPI0707948-6A patent/BRPI0707948A2/pt not_active Application Discontinuation
- 2007-02-16 EP EP07757135A patent/EP1989225A2/en not_active Withdrawn
- 2007-02-16 WO PCT/US2007/062335 patent/WO2007098415A2/en not_active Ceased
- 2007-02-16 US US12/279,028 patent/US8653039B2/en active Active
-
2014
- 2014-02-18 US US14/182,550 patent/US9187526B2/en active Active
-
2015
- 2015-10-29 US US14/926,904 patent/US20160304559A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9187526B2 (en) | 2015-11-17 |
| EP1989225A2 (en) | 2008-11-12 |
| CN101384618A (zh) | 2009-03-11 |
| BRPI0707948A2 (pt) | 2011-05-17 |
| US20140296156A1 (en) | 2014-10-02 |
| US20090232882A1 (en) | 2009-09-17 |
| CA2638866A1 (en) | 2007-08-30 |
| US20160304559A1 (en) | 2016-10-20 |
| WO2007098415A3 (en) | 2007-12-13 |
| US8653039B2 (en) | 2014-02-18 |
| AU2007217037A1 (en) | 2007-08-30 |
| WO2007098415A2 (en) | 2007-08-30 |
| JP2009527498A (ja) | 2009-07-30 |
| EA200801847A1 (ru) | 2009-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8653039B2 (en) | Peptide based inhibition of caPCNA interaction in cancer | |
| US10188699B2 (en) | CAPCNA peptide therapeutics for cancer | |
| KR101653774B1 (ko) | 올리고펩타이드 화합물 및 이의 용도 | |
| CA2732737C (en) | Cancer peptide therapeutics | |
| Machida et al. | A novel adenine nucleotide translocase inhibitor, MT-21, induces cytochrome c release by a mitochondrial permeability transition-independent mechanism | |
| JP6408555B2 (ja) | 融合タンパク質及びブロモドメイン阻害化合物の識別方法 | |
| CA2575123A1 (en) | Peptide sequence for modulation of delta protein kinase c | |
| US9593148B2 (en) | DPP8 and DPP9 peptide inhibitors | |
| Bendzunas | All Hydrocarbon Stapled Peptides as Allosteric Modulators of Protein-Protein Interactions | |
| KR20250047483A (ko) | Braf 활성 억제 단백질 및 이를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물 | |
| EP2429563B1 (en) | Peptide able to disrupt the protein complex between the his273 mutated p53 protein and the oncosuppressive p73 protein in tumour cells and therapeutic uses thereof | |
| EP2578227B1 (en) | Cancer therapy method | |
| Merwin | A C-terminus mitochondrial-localization region and BH3 Domain of Puma are required for apoptotic function | |
| Teichmann et al. | Modulation of SHP‐1 phosphatase activity by monovalent and bivalent SH2 phosphopeptide ligands | |
| HK1214177B (en) | Cancer peptide therapeutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD Year of fee payment: 18 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250207 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250207 |